IMO there is a distinct risk of Abeyratne’s work not reaching its potential because of the sell-out.
Once it’s commercial value had been established by Medgate and Alodokter there was every likelihood of other telehealth providers coming in to approach ResApp seeking similar contracts. They may be far more reluctant now in needing to deal with Pfizer, considering its reputation.
Only an issue that would be of concern to the long-term holders of course.
- Forums
- ASX - By Stock
- RAP
- Ann: Notification of cessation of securities - RAP
Ann: Notification of cessation of securities - RAP, page-22
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
Add RAP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable